Physician profile
Abigail N Schwaede
NPI 1861810822
$73,166.58
in general payments reported to CMS, 2019-2025
20 companies · $39K in 2025
The $39K reported for 2025 was more than what 90% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2021: $48.45 · 2022: $259 · 2023: $9,496 · 2024: $24K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $3,884 · Food and Beverage: $2,838 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,207.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,645.00 |
| Travel and Lodging | $3,883.99 |
| Food and Beverage | $2,837.56 |
| Education | $140.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $28,030.09 | 2022-2025 | Elevidys |
| Janssen Biotech, INC. | $18,137.04 | 2025 | |
| Biogen, INC. | $9,298.30 | 2022-2025 | Spinraza, Skyclarys |
| Johnson & Johnson Health Care Systems INC. | $5,589.74 | 2024 | |
| Novartis Pharmaceuticals Corporation | $5,192.92 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $4,653.26 | 2025 | |
| Genentech, INC. | $1,486.44 | 2023 | Evrysdi |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $193.24 | 2023 | Zolgensma |
| Akcea Therapeutics, INC. | $122.15 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $116.41 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $72.87 | 2021-2022 | |
| Ns Pharma, INC. | $61.57 | 2024-2025 | Viltepso |
| Itf Therapeutics LLC | $61.35 | 2025 | |
| Argenx US, INC. | $55.50 | 2025 | |
| Genentech USA, INC. | $29.11 | 2023 | Evrysdi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $25.49 | 2022 | |
| Csl Behring | $23.21 | 2019 | |
| Ptc Therapeutics, INC. | $17.89 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Schwaede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.